Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 18/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357228 | 1.00 | ALOX5 (0.64) | ALOX5MAPTMEN1ALDH1A1TP53 | |
| SCHEMBL12509164 | 0.88 | ALOX5 (0.53) | ALOX5 | |
| SCHEMBL8807487 | 0.79 | ALOX5 (0.69) | ALOX5 | |
| SCHEMBL6438420 | 0.78 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL9201328 | 0.78 | ALOX5 (1.00) | ALOX5MAPTMEN1ALDH1A1TP53 | |
| SCHEMBL9201340 | 0.78 | ALOX5 (1.00) | ALOX5MAPTMEN1ALDH1A1TP53 | |
| SCHEMBL1807930 | 0.78 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL8590069 | 0.78 | ALOX5 (1.00) | ALOX5 | |
| SCHEMBL8806155 | 0.77 | ALOX5 (0.74) | ALOX5MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL9365720 | 0.77 | ALOX5 (0.57) | ALOX5MAPTMEN1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288551-B2 | Targeted nitroxide agents | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-08-16 | — | — | US | disclosed |
| US-20120004263-A1 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010009405-A9 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2010-02-11 | — | — | US | disclosed |
| WO-2010009405-A2 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207687-A1 | TOPICAL FORMULATIONS OF TARGETED NITROXIDE AGENTS | NOX1, OGG1, NOX5 | ALOX5 549/4885MAPT 1156/4885MEN1 4054/4885 |
| US-20120004263-A1 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | GLA, AGER, SIRT1 | ALOX5 695/4885MAPT 143/4885MEN1 3812/4885 |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | HAGH, COX5B, HSPE1 | ALOX5 932/4885MAPT 3147/4885MEN1 4374/4885 |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ALOX5 2163/4885MAPT 1583/4885MEN1 3895/4885 |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885MAPT 2546/4885MEN1 3370/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ALOX5 10/4885MAPT 4859/4885MEN1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.